Intern Med . Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma

[tetano]

Intern Med


. 2022 May 31.
doi: 10.2169/internalmedicine.9136-21. Online ahead of print.
Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma


Yayoi Ueda ¹ , Shoji Asakura ¹ , Sae Wada ² , Takashi Saito ³ , Tomofumi Yano ¹



Affiliations

• PMID: 35650124
• DOI: 10.2169/internalmedicine.9136-21

Abstract

A patient with follicular lymphoma treated with obinutuzumab and bendamustine experienced prolonged coronavirus disease-2019 (COVID-19). One month after the symptoms transiently improved, the patient experienced exacerbated COVID-19 symptoms. The patient recovered from COVID-19 with remdesivir and dexamethasone and was discharged 77 days after the disease onset. The patient completed a primary series of SARS-CoV-2 vaccinations on day 176, but the anti-spike protein IgG was not detected later. A careful observation to detect any subsequent relapse of COVID-19 symptoms is necessary in immunocompromised patients. Chemotherapy should be based on the disease status and type of lymphoma.

Keywords: follicular lymphoma; immunocompromised patient; obinutuzumab and bendamustine; prolonged COVID-19.